Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer
Open Access
- 1 November 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 15 (11) , 2598-2608
Abstract
Metastatic breast cancer is an incurable disease and identification of novel therapeutic opportunities is vital. Triple-negative breast cancer (TNBC) frequently metastasizes and high levels of activated p90RSK (RSK), a downstream MEK-ERK1/2 effector, are found in TNBC. We demonstrate, using direct pharmacologic and genetic inhibition of RSK1/2, that these kinases contribute to the TNBC metastatic process in vivo. Kinase profiling showed that RSK1 and RSK2 are the predominant kinases targeted by the new inhibitor, which is based on the natural product SL0101. Further evidence for selectivity was provided by the observations that silencing RSK1 and RSK2 eliminated the ability of the analogue to further inhibit survival or proliferation of a TNBC cell line. In vivo, the new derivative was as effective as the FDA-approved MEK inhibitor trametinib in reducing the establishment of metastatic foci. Importantly, inhibition of RSK1/2 did not result in activation of AKT, which is known to limit the efficacy of MEK inhibitors in the clinic. Our results demonstrate that RSK is a major contributor to the TNBC metastatic program and provide preclinical proof-of-concept for the efficacy of the novel SL0101 analogue in vivo. Mol Cancer Ther; 15(11); 2598–608. ©2016 AACR.Keywords
All Related Versions
Funding Information
- NIH (GM088839)
- NSF (CHE-1565788)
This publication has 52 references indexed in Scilit:
- Improving the Affinity of SL0101 for RSK Using Structure-Based DesignACS Medicinal Chemistry Letters, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophilesNature Chemical Biology, 2012
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- RSK in tumorigenesis: Connections to steroid signalingSteroids, 2010
- RSK1 drives p27Kip1phosphorylation at T198 to promote RhoA inhibition and increase cell motilityProceedings of the National Academy of Sciences, 2009
- Codependent Functions of RSK2 and the Apoptosis-Promoting Factor TIA-1 in Stress Granule Assembly and Cell SurvivalMolecular Cell, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent TranslationJournal of Biological Chemistry, 2007
- A clickable inhibitor reveals context-dependent autoactivation of p90 RSKNature Chemical Biology, 2007